BioSpace News Archive

Illumina, Inc. announced its financial results for the second quarter of fiscal year 2018.

Conference Call and webcast to follow

Revenue was $170.1 million in the second quarter of 2018. (Under ASC 605, net service revenue of $117.8 million increased 24.6% from net service revenue of $94.6 million for the comparable prior-year period, representing a backlog conversion rate of 21.5%.)

Kalorama Information noted the following interesting new products and other developments at the upcoming Clinical Expo and in the current sessions of the American Association for Clinical Chemistry 2018, which is underway in Chicago, IL.

Study aims to evaluate the cellular destruction and immune response driven by Nano-Pulse Stimulation

BIOASIS TECHNOLOGIES INC. announced that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended May 31, 2018.

Astex Pharmaceuticals announce top-line results from the ASTRAL-1 study evaluating the efficacy and safety of guadecitabine (SGI-110) in adults with previously untreated AML who are not eligible for intensive induction chemotherapy.

Oticon Medical announced that John Sparacio has been named as President, Oticon Medical US

Adlai Nortye Corporation, a leading biotech company in China, today announced a biomarker analysis publication by the investigators from the phase II study BERIL-1 Buparlisib/Paclitaxel vs Paclitaxel in 2nd Line HNSCC. The study was published by Clinical Cancer Research, June 2018, volume 24, issue 11, titled “Molecular Alterations and Buparlisib Efficacy in Patients With Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis From BERIL-1".

Health care workers at Port Arthur Health Centre, Unifor Local 229 members, will be asking to speak to municipal officials at a City Council meeting in Thunder Bay on Monday, July 30, 2018.